Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A PARP1-TIMELESS alliance in cancer therapy.

Tarsounas M., (2024), Mol Cell, 84, 1824 - 1825

Targeting DNA damage response pathways in cancer

Groelly FJ. et al, (2022), Nature Reviews Cancer

DNA Damage and Cancer Immunotherapy: a STING in the Tale.

Reisländer T. et al, (2020), Mol Cell

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.

Tarsounas M. and Sung P., (2020), Nat Rev Mol Cell Biol

Tc-99m-duramycin imaging reveals variable tissue toxicity of cancer drugs

Sneddon D. et al, (2018), JOURNAL OF NUCLEAR MEDICINE, 59

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

Tacconi EM. et al, (2017), EMBO Mol Med, 9, 1398 - 1414

Load More